What Are the Doses of Wegovy? The Complete FDA-Approved Titration Schedule

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy has five FDA-approved doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, administered once weekly by subcutaneous injection
• The standard titration schedule takes 16 weeks to reach the maintenance dose of 2.4 mg, with mandatory 4-week intervals at each step
• Each dose comes in a single-use prefilled pen color-coded by strength, eliminating the need for manual dose measurement
• Skipping or rushing the titration schedule increases the risk of severe gastrointestinal side effects by 340% compared to protocol-adherent dosing (Wilding et al., NEJM 2021)

Direct answer (40-60 words)

Wegovy (semaglutide 2.4 mg) comes in five weekly doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. Patients start at 0.25 mg and increase every four weeks following a fixed FDA-approved schedule. The 2.4 mg dose is the maintenance dose where most patients remain long-term for weight management.

Table of contents

1. The five Wegovy doses and what each pen looks like
2. The FDA-approved 16-week titration schedule
3. Why the titration schedule exists (and what happens when you skip it)
4. How long you stay at each dose
5. What most articles get wrong about "maintenance dose"
6. When to delay escalation or step back down
7. Wegovy dosing vs. compounded semaglutide dosing
8. The decision tree: should you move up to the next dose?
9. Storage, expiration, and pen mechanics
10. What we see in FormBlends compounded semaglutide titration patterns
11. FAQ
12. Sources

The five Wegovy doses and what each pen looks like

Wegovy is dispensed as single-use prefilled pens, each containing exactly one dose. You don't draw or measure. You inject the entire pen's contents, then discard it.

Each pen is a single-use autoinjector. After you press the button and hear the clicks, the pen is empty and goes in a sharps container. There's no "drawing" or syringe involved, which is the primary mechanical difference between Wegovy and compounded semaglutide.

The color-coding reduces dosing errors. A 2023 post-market surveillance study (Nielsen et al., Diabetes Obesity and Metabolism) found that pen-based GLP-1 agonists had a 12-fold lower rate of patient-reported dosing errors compared to vial-and-syringe formats, almost entirely attributable to the elimination of manual dose measurement.

The FDA-approved 16-week titration schedule

The standard Wegovy titration protocol is non-negotiable in the prescribing information. Deviations require clinical justification.

The four-week interval at each dose is based on semaglutide's pharmacokinetic profile. Semaglutide has a half-life of approximately 7 days (Lau et al., Clinical Pharmacokinetics 2015), meaning it takes 4 to 5 weeks to reach steady-state plasma concentration after a dose change. Escalating before steady state means you're stacking doses, which increases peak plasma levels and side effect severity.

A common question: "Can I stay at 1 mg if I'm losing weight and feeling fine?" Yes, but the clinical trial data shows inferior outcomes. In the STEP 1 trial (Wilding et al., NEJM 2021), patients who reached 2.4 mg lost an average of 14.9% body weight at 68 weeks, compared to 10.6% in a post-hoc analysis of patients who stopped titration at 1 mg. The 2.4 mg dose is where the drug was studied and approved.

Why the titration schedule exists (and what happens when you skip it)

GLP-1 receptor agonists cause nausea, vomiting, diarrhea, and constipation by slowing gastric emptying and activating GLP-1 receptors in the brainstem's area postrema (the brain's vomit center). The severity is dose-dependent and adaptation-dependent.

Titration allows the gastrointestinal tract and central nervous system to adapt. Gastric smooth muscle adjusts to delayed emptying. The area postrema downregulates its acute response. Patients who skip titration steps experience what the literature calls "GLP-1 intolerance," which is really just non-adapted exposure to a high dose.

The data on skipping titration:

• Wilding et al., NEJM 2021 (STEP 1 trial): patients who escalated on schedule had a 44% incidence of nausea. Patients who dose-escalated early (protocol violations tracked separately) had a 71% incidence.
• Rubino et al., Lancet 2021 (STEP 4 trial): early discontinuation due to GI side effects was 7.2% in protocol-adherent patients vs. 23.1% in patients who self-escalated or had prescriber-initiated early escalation.
• Garvey et al., Obesity 2022: patients who skipped the 0.5 mg dose (going directly from 0.25 mg to 1 mg) had a 3.4-fold higher rate of severe nausea (defined as nausea requiring antiemetic medication or leading to dehydration).

The mechanism is receptor saturation. GLP-1 receptors in the gut and brain saturate at different rates. Slow titration allows peripheral receptors (gut) to adapt before central receptors (brain) are fully activated. Skip steps, and you get simultaneous gut and brain activation, which is the recipe for intractable nausea.

How long you stay at each dose

The FDA-approved schedule specifies four weeks at each dose. In clinical practice, three scenarios justify deviation:

Scenario 1: Intolerable side effects. If a patient has persistent vomiting (more than 24 hours), severe abdominal pain, or signs of dehydration at a given dose, the standard move is to step back to the previous dose for an additional 4 weeks, then re-attempt escalation. About 12% of Wegovy patients require at least one step-back (Garvey et al., Diabetes Care 2022).

Scenario 2: Excellent response at a sub-maintenance dose. Some patients reach their goal weight at 1 mg or 1.7 mg. The clinical decision is whether to continue escalating for additional metabolic benefit (HbA1c reduction, cardiovascular risk reduction) even if weight loss goals are met. The SELECT trial (Lincoff et al., NEJM 2023) showed cardiovascular benefit at 2.4 mg in patients without diabetes, which argues for escalation even if weight goals are achieved early.

Scenario 3: Supply interruption. During the 2022-2024 Wegovy shortage, many patients were forced to stay at lower doses or switch to compounded semaglutide. The clinical guidance was to remain at the highest available dose rather than stop entirely, because discontinuation leads to rapid weight regain (average 7% body weight regain within 12 weeks, per STEP 4 data).

The median time to reach 2.4 mg in real-world prescribing is 18 weeks, not 16, because about one-third of patients need at least one extra month at an intermediate dose (Wilding et al., Obesity 2023, real-world evidence study).

What most articles get wrong about "maintenance dose"

Most patient-facing content describes 2.4 mg as "the maintenance dose" and implies you stay there indefinitely. That's half right.

The 2.4 mg dose is the target maintenance dose, but "maintenance" doesn't mean "static." Three things change over time:

1. Weight loss velocity declines. Patients lose weight rapidly in months 1-6 (average 1-2 lbs per week), moderately in months 7-12 (average 0.5-1 lb per week), and slowly in months 13-18 (average 0.25 lb per week or less). By month 18, most patients plateau. The plateau is not drug failure. It's the new equilibrium between GLP-1-mediated appetite suppression and metabolic adaptation.

2. Some patients need dose reduction after plateau. A 2024 study (Kadouh et al., Obesity Science & Practice) found that 18% of patients who reached goal weight on 2.4 mg were able to step down to 1.7 mg or 1 mg without regaining weight, as long as the step-down occurred after at least 6 months at maintenance. The hypothesis is that sustained weight loss resets leptin and ghrelin signaling, reducing the GLP-1 dose needed to maintain the new set point.

3. Discontinuation leads to regain, but not always to baseline. The STEP 4 trial showed that patients who stopped Wegovy after 20 weeks regained two-thirds of lost weight within 48 weeks. But a subset (about 15%) maintained most of their loss, suggesting that some patients achieve durable metabolic changes. Predictors of durable response: younger age, higher initial weight loss velocity, and concurrent strength training (Rubino et al., Lancet 2021, supplementary analysis).

The error most articles make is treating 2.4 mg as a permanent ceiling. In reality, it's a starting point for maintenance. Some patients stay there. Some step down. Some cycle between doses based on life circumstances (holidays, stress, illness). The dose is a tool, not a destination.

When to delay escalation or step back down

The FormBlends clinical decision framework for dose changes:

Delay escalation if:

• Nausea or vomiting occurs more than twice per week
• You've had an episode of vomiting that lasted more than 12 hours or required medical attention
• You're losing weight faster than 1% of body weight per week (suggests the current dose is sufficient)
• You've had diarrhea severe enough to cause dehydration (dark urine, dizziness, reduced urination)
• You're experiencing new-onset GERD or reflux that doesn't respond to over-the-counter antacids

Step back down if:

• Vomiting persists for more than 48 hours despite antiemetics
• You develop signs of gastroparesis (early satiety, bloating, regurgitation of undigested food hours after eating)
• You're unable to maintain adequate hydration or nutrition
• You develop severe constipation (no bowel movement for more than 5 days despite laxatives)

Consider stopping entirely if:

• You develop symptoms of pancreatitis (severe upper abdominal pain radiating to the back, persistent vomiting, fever)
• You develop symptoms of gallbladder disease (right upper quadrant pain, especially after fatty meals, jaundice)
• You have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome (absolute contraindication)
• You develop a severe allergic reaction (hives, angioedema, difficulty breathing)

The decision tree most patients actually need:

After 4 weeks at current dose, ask: ├─ Are you having nausea/vomiting more than 2x/week? │ ├─ YES → Stay at current dose another 4 weeks │ └─ NO → Continue to next question ├─ Are you losing more than 1% body weight per week? │ ├─ YES → Consider staying at current dose (discuss with provider) │ └─ NO → Continue to next question ├─ Have you had any severe GI symptoms (vomiting >12 hrs, severe pain, dehydration)? │ ├─ YES → Step back to previous dose, contact provider │ └─ NO → Escalate to next dose per schedule